Advisory Group Supports Industry Demand For Audit Of WHO Pandemic Flu Framework 05/04/2017 by Catherine Saez, Intellectual Property Watch 2 Comments The World Health Organization has been recommended to provide details on its spending of funds provided to its pandemic influenza framework by the private sector.
Public-Private Coalition’s High-Profile Delinkage Policy For Emerging Vaccines 04/04/2017 by Tatum Anderson for Intellectual Property Watch 1 Comment It’s early February in Tchaourou district, Borgou in Benin, and a pregnant woman is admitted to hospital. Her premature baby is born by caesarean section but she dies a day later on February 12th. It turns out she had Lassa fever, a deadly viral haemorrhagic disease. But that’s only discovered after the baby is discharged from hospital and taken to northern Togo. The newborn also becomes ill and is taken to hospital for treatment.
The Current And Future Scope Of IPR Estoppel 04/04/2017 by Intellectual Property Watch Leave a Comment David I. Berl and Christopher A. Suarez write: The estoppel provision of the America Invents Act, 35 U.S.C. 315(e), was touted originally as a check against patent challengers using inter partes review (“IPR”) proceedings to attack patents serially on the same or similar grounds. That provision precludes an IPR petitioner, or the real party in interest or privy of the petitioner, from asserting invalidity challenges in subsequent IPR, district court, or International Trade Commission (“ITC”) proceedings “on any ground that the petitioner raised or reasonably could have raised during” an IPR that resulted “in a final written decision.” Given the frequency of IPR and associated district court challenges, the scope of the AIA’s estoppel provision, with respect to the parties and arguments it estops, has become and will continue to be a critical and frequently contested issue for litigants.
Report Finds Wide Gap In Pharma Companies’ Profits And Spending On R&D 03/04/2017 by Intellectual Property Watch 2 Comments A new report from Public Citizen, the US-based consumer rights advocacy group, shows that the 20 largest pharmaceutical corporations are spending significantly less on research and development of new medicines than they are making in profits.
WIPO Committee Moves Ahead On Country Names, Tech Designs, Not GIs 03/04/2017 by Catherine Saez, Intellectual Property Watch Leave a Comment Establishing a work programme on geographical indications at the World Intellectual Property Organization last week proved elusive. A tentative text and time frame by the chair of the committee on trademark and geographical indications (GIs) issued on the last day of the committee did not meet the approval of some member states. The committee did agree on a set of tasks for the WIPO secretariat on the protection of country names against registration as trademarks, and on the protection of new technological designs, such as icons and type fonts.
Special Report: Will The Internet Of Things Need New Patenting/Licensing Strategies? 03/04/2017 by Dugie Standeford for Intellectual Property Watch Leave a Comment The Internet of Things (IoT), which will connect billions of devices in coming years, may offer incredible opportunities for businesses and consumers but it also raises significant intellectual property issues, IP lawyers, mobile operators and others say. One key question is whether patenting and licensing strategies will have to change to adapt to the myriad standards being developed and patents being sought for IoT products and services, and for the coming rollout of 5G technologies.
Report: Market Share Of Orphan Drugs Could Top 20 Percent Of Global Market By 2022 03/04/2017 by Intellectual Property Watch Leave a Comment A new industry report shows that the average prices for orphan drugs are increasing and are projected to comprise more than 20 percent of the patented pharmaceutical sales market by 2022.
France Reaches Agreement With Gilead To Drop Prices Of Hepatitis C Treatment 31/03/2017 by Intellectual Property Watch 2 Comments The French Ministry of Social Affairs and Health announced today that the ministry has negotiated with pharmaceutical company Gilead to bring down the prices of hepatitis C medicines.
US Congress Considers Plan For Presidential Appointment Of Copyright Register 31/03/2017 by Dugie Standeford for Intellectual Property Watch 1 Comment Legislation authorising the president to appoint the Register of Copyright in the United States Copyright Office is working its way through Congress. The “Register of Copyrights Selection and Accountability Act” garnered strong bipartisan support in the House of Representatives Judiciary Committee as well as from the content community, but others fear it will politicise the […]
NGOs Detail Changes For Public Health In RCEP Asian Trade Pact 31/03/2017 by Catherine Saez, Intellectual Property Watch 1 Comment Concerns continue to grow among civil society about provisions in a major trade agreement in the Asian region. Of specific worry is the intellectual property chapter containing in particular a data exclusivity clause, and the linkage between the investment chapter and the IP chapter.